Parotid tuberculosis

Garg, Rajiv; Verma, Sanjay Kumar; Mehra, Sumit; Srivastawa, A. N.
October 2010
Lung India;Oct-Dec2010, Vol. 27 Issue 4, p253
Academic Journal
Case Study
Tuberculosis of the parotid gland is a rare condition. We describe a case of tuberculosis of right parotid gland in a 17-year-old male patient. Diagnosis was made by early suspicion and confirmed by demonstration of epitheloid granulomas on fine needle aspiration cytology (FNAC). Patient was successfully treated with daily regimen of four drugs (rifampicin, isoniazid, pyrazinamide, ethambutol) for first two months followed by two drugs (rifampicin and isoniazid) for last four months.


Related Articles

  • Nonsteroidal Antiinflammatory Drugs for Adjunctive Tuberculosis Treatment. Ivanyi, Juraj; Zumla, Alimuddin // Journal of Infectious Diseases;Jul2013, Vol. 208 Issue 2, p185 

    The article offers information on the role and efficacy of nonsteroidal anti-inflammatory drugs for adjunctive tuberculosis treatment. It adds that despite of the availability of effective treatment since the 1970 tuberculosis continues to cause 1.4 million deaths annually. As mentioned, the...

  • Presumed tuberculous retrobulbar optic neuritis: a diagnosis challenge. Aupy, Jérôme; Vital, Anne; Rougier, Marie-Benedicte; Gradel, Antoine; Meissner, Wassilios; Marchal, Cecile; Penchet, Guillaume; Brochet, Bruno // Journal of Neurology;Feb2015, Vol. 262 Issue 2, p481 

    The article discusses the case of a female patient diagnosed with isolateral unilateral retrobulbar optic neuritis (RBOB) due to tuberculosis (TB). Topics discussed include the patient's clinical presentation which includes painless blurred vision in the right eye with red/green dyschromatopsia,...

  • Elevated gatifloxacin and reduced rifampicin concentrations in a single-dose interaction study amongst healthy volunteers. Helen McIlleron; Jennifer Norman; Thomas P. Kanyok; P. Bernard Fourie; John Horton; Peter J. Smith // Journal of Antimicrobial Chemotherapy (JAC);Dec2007, Vol. 60 Issue 6, p1398 

    Objectives Pharmacokinetic drug–drug interactions were investigated between the fluoroquinolone gatifloxacin and a fixed dose combination (FDC) of rifampicin, isoniazid and pyrazinamide. Patients and methods The single-dose pharmacokinetics of the four drugs was evaluated in an...

  • Safety of 3 Different Reintroduction Regimens of Antituberculosis Drugs after Development of Antituberculosis Treatment-Induced Hepatotoxicity. Sharma, Surendra K.; Singla, Rohit; Sarda, Pawan; Mohan, Alladi; Makharia, Govind; Jayaswal, Arvind; Sreenivas, Vishnubhatla; Singh, Sarman // Clinical Infectious Diseases;3/15/2010, Vol. 50 Issue 6, p833 

    Background. Drug-induced hepatotoxicity (DIH) is the most common adverse drug reaction leading to interruption of antituberculosis treatment. Worldwide, different reintroduction regimens have been advocated, but no consensus guidelines are available. Reintroduction of antituberculosis drugs in...

  • Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana. Chideya, Sekai; Winston, Carla A.; Peloquin, Charles A.; Bradford, William Z.; Hopewell, Philip C.; Wells, Charles D.; Reingold, Arthur L.; Kenyon, Thomas A.; Moeti, Themba L.; Tappero, Jordan W. // Clinical Infectious Diseases;6/15/2009, Vol. 48 Issue 12, p1685 

    Background. We explored the association between antituberculosis drug pharmacokinetics and treatment outcomes among patients with pulmonary tuberculosis in Botswana. Methods. Consenting outpatients with tuberculosis had blood samples collected 1, 2, and 6 h after simultaneous isoniazid,...

  • TB Therapy Effective in CKD Patients. SCHIESZER, JOHN // Renal & Urology News;Dec2012, Vol. 11 Issue 12, p14 

    The article focuses on the results of the 12-month study of 572 patients with chronic kidney disease (CKD) conducted by the researchers in India. It says that the CKD patients who were diagnosed with tuberculosis (TB) were included and each of them was started on anti-tuberculosis treatment...

  • Advances in the development of new tuberculosis drugs and treatment regimens. Zumla, Alimuddin; Nahid, Payam; Cole, Stewart T. // Nature Reviews Drug Discovery;May2013, Vol. 12 Issue 5, p388 

    Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs...

  • Phosphorylation of ΔNp63α via a Novel TGFβ/ALK5 Signaling Mechanism Mediates the Anti-Clonogenic Effects of TGFβ. Cherukuri, Pratima; DeCastro, Andrew J.; Balboni, Amanda L.; Downey, Sondra L.; Liu, Jennifer Y.; Hutchinson, Justine A.; DiRenzo, James // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Genetic analysis of TP63 implicates ΔNp63 isoforms in preservation of replicative capacity and cellular lifespan within adult stem cells. ΔNp63α is also an oncogene and survival factor that mediates therapeutic resistance in squamous carcinomas. These diverse activities are the result...

  • Treatment of isoniazid-resistant pulmonary tuberculosis. Yee Hyung Kim; Gee Young Suh; Man Pyo Chung; Hojoong Kim; O. Jung Kwon; Seong Yong Lim; Si Young Lim; Won-Jung Koh // BMC Infectious Diseases;2008, Vol. 8 Issue 1, Special section p1 

    Background: Although resistance to isoniazid (INH) is the most common form of drug resistance seen among Mycobacterium tuberculosis isolates, there have been few studies on the efficacy and optimal duration of treatment for patients with INH-resistant tuberculosis (TB). Methods: We evaluated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics